Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma
II期INTERACT-ION研究：伊扎贝利单抗（BI 754091）联合mDCF（多西他赛、顺铂和5-氟尿嘧啶）化疗后序贯放化疗治疗III期肛门鳞状细胞癌患者
期刊:Frontiers in Oncology
影响因子:3.3
doi:10.3389/fonc.2022.918499
Kim, Stefano; Boustani, Jihane; Vernerey, Dewi; Vendrely, Véronique; Evesque, Ludovic; Francois, Eric; Quero, Laurent; Ghiringhelli, Francois; de la Fouchardière, Christelle; Dahan, Laëtitia; Bouché, Oliver; Chibaudel, Benoist; Hajbi, Farid El; Vernet, Chloé; Rebucci-Peixoto, Magali; Feuersinger, Alexandra; Maritaz, Christophe; Borg, Christophe
